PARP1 and chronic myelogenous leukemia, BCR-ABL1 positive: In both primary IM-sensitive and IM-resistant CML cells, P22077 treatment decreases YB-1 but increases the expression of γH2AX and the cleavage of caspase-3 and PARP1, indicating the activation of apoptosis (Fig. 7f).